|
|
Oct 22, 2011
Journal post from David Baker
Today's issue of Science magazine describes an exciting new approach to HIV vaccine design using Rosetta. In contrast with other viruses such as polio and influenza, inactivated HIV or HIV proteins have not worked as vaccines, and hence as you know there is currently no effective HIV vaccine. Our approach to vaccine design is to take the bits of the HIV surface protein that people make antibodies to, and using Rosetta graft them onto small stable scaffolds that can be made in large quantities and potentially could be useful as vaccines. We've shown earlier that this can be done straightforwardly with Rosetta if the bits of the HIV protein are contiguous along the sequence, but it is much harder if the antibody recognizes multiple bits close in three dimensions but far in sequence. In this paper we show how such "discontinuous" epitipes can be transferred from HIV gp120 to a simple scaffold protein. More work will be required to determine whether this or other vaccine candidates designed using this approach will be effective as HIV vaccines-let us all hope so!!
用google翻译的，专业的同学不妨准确翻译一下：
今天的“科学”杂志上描述了一个艾滋病毒疫苗的设计令人振奋的新方法，使用Rosetta。在对比与其他病毒，如脊髓灰质炎和流感灭活艾滋病毒或艾滋病毒的蛋白质没有担任过疫苗，并因此如你所知，目前还没有有效的艾滋病病毒疫苗。疫苗的设计，我们的做法是采取艾滋病毒表面蛋白的位，人们作出的抗体，并使用Rosetta移植到小，可大量可能有用的疫苗的稳定支架。我们已经证明，这是可以做到直截了当地与罗塞塔如果艾滋病毒蛋白的位序列沿着连续的，但它是非常困难，如果抗体识别接近，但顺序在三个维度的多个位。在本文中，我们展示了如何将这样的“不连续”epitipes可以从艾滋病毒gp120的转移到一个简单的支架蛋白。将需要更多的工作，以确定是否或其他疫苗采用这种方法设计的候选人将有效的艾滋病毒的疫苗让我们大家都希望如此！ |
|
发表于 2011-11-3 10:18:41
发表于 2011-11-3 16:17:00
。